CEFObio
CEFObio Co., Ltd was founded in September 2011 to conduct research and development for cell-based therapy products and commercialize them. During the start-up period, we focused on establishing basic technologies for developing cell therapy such as 3D cell culture systems, and developing elemental technologies (culture medium, enzymes and culture wear, etc.) for cell therapy.
Since then, CEFObio developed a cell therapy by applying 3D culture technology, a secured original technology. The factory was completed in 2019 and began producing cell therapy for clinical trials in 2020. It also commercialized culture factors, such as culture medium, enzymes, and cryosolution for cell-related therapy products by producing them in accordance with ISO13485.
In July 2021, a phase 1 clinical trial of CF-M801 for the rare disease osteonecrosis of the femoral head (ONFH) was approved by the regulatory agency. The trial was completed in June 2023. CF-M801 is a cluster of umbilical cord-derived osteoblast cells. These cells are differentiated from umbilical cord-derived mesenchymal stem cells into osteoblasts.
In addition, we are rapidly expanding the indications for spinal fusion, fractures, etc. We are currently applying for phase 2 clinical trials of CF-M801 for fragility fractures. Non-clinical trials for spinal fusion have been completed.
In October 2023, the excellence of the cell therapy under development was proven by receiving the New Excellent Technology certification. Additionally, we are developing chondrocyte and immune cell therapies through new pipelines.
CEFObio is a cutting-edge biopharmaceutical technology development company that aims to contribute to the advancement of medical technology through know-how and technological innovation accumulated through many years of stem cell and culture optimization research and development.
For more information, visit: https://cefobio.com
